In the original article, we neglected to include the funder National Natural Science Foundation of China, 81802779 to Jun Li; Henan Provincial Health Commission, SBGJ202002020 to Jun Li; and Henan Science and Technology Project, 212102310675 to Jun Li.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
BRCA1/2, haplotype analysis, ovarian cancer, founder mutation, Chinese
Citation
Li J, Han S, Zhang C, Luo Y, Wang L, Wang P, Wang Y, Xia Q, Wang X, Wei B, Ma J, Li H and Guo Y (2022) Corrigendum: Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients. Front. Oncol. 11:840551. doi: 10.3389/fonc.2021.840551
Received
21 December 2021
Accepted
22 December 2021
Published
14 January 2022
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
11 - 2021
Updates
Copyright
© 2022 Li, Han, Zhang, Luo, Wang, Wang, Wang, Xia, Wang, Wei, Ma, Li and Guo.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yongjun Guo, guoyongjun@zzu.edu.cn; Hongle Li, llhl73@163.com
†These authors have contributed equally to this work and share first authorship
This article was submitted to Gynecological Oncology, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.